// App-Quantinova.ai

P378 : Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: Results from OCTAVE Open

Researchers

Presenter

  • Allegretti, J.R

Principal Investigators

  • Gecse, K.B

  • Chiorean, M.V

  • Argollo, M

  • Guo, X

  • Lawendy, N

  • Su, C

  • Mundayat, R

  • Paulissen, J

  • Salese, L

  • Irving, P.M

Medical Centers

  • Brigham and Women's Hospital, Division of Gastroenterology, Hepatology, and Endoscopy, Boston, United States

  • Swedish Medical Center, Seattle, WA, United States

  • Federal University of Sao Paulo, Department of Pharmacology, São Paulo, Brazil

  • Pfizer Inc., Collegeville, United States

  • Pfizer Inc., New York, United States

Locations

  • United States

  • Netherlands

  • Brazil

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

Biomarkers

  • N/A

Drug/Treatment

  • Tasocitinib

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved